19 oktober 2016: Dr. Burzynski is op nagenoeg alle punten vrijgesproken en mag weer als arts werken en zijn antineoplastons gebruiken. Hier het artikel met de uitspraak van het Texaanse Gerechtshof waar ik me niet aan waag om dit te vertalen want is te technisch voor mij. Maar belangrijkste is dat Dr. Burzynski weer mag werken als arts. 

https://kanker-actueel.nl/NL/dr-burzynski-heeft-veel-succes-met-zijn-aanpak-van-kanker-een-overzicht-van-belangrijke-publicaties-over-de-methode-van-dr-burzynski.html

We ontvingen de laatste resultaten (d.d. november 2001) van Arnold Gore uit een paar trials die gaande zijn in de USA met de antineoplastontherapie van Burzinsky. Hierbij ongewijzigd en in het Engels de resultaten zoals wij die van Arnold Gore  doorkregen. (deze studie resultaten zijn in het Engels, de resultaten van enkele trials elders op deze pagina zijn vertaald in het Nederlands en bevestigen onderstaande resultaten)

Results Of Brain Tumor Trials As Of Nov. 2001.

Over 100 clinical trials using different chemotherapy regimens have been conducted on recurrent brain tumors. The general consensus is that such tumors cannot be cured by chemotherapy and the response rate is only modest. Complete responses are almost never seen, and the total response rate usually includes stable disease. Even though some of these studies report significant responses, the durations of improvement are short. Ultimately, almost all of these patients die from their brain tumors. Patients who are being treated with antineoplaston therapy often are the exception.

Antineoplaston therapy has been used to treat neoplastic disease since the 1970s. Patients can tolerate administration of antineoplastons very well, for as long as approximately 10 years in one case. The
Burzynski Research Institute currently sponsors 72 different Phase II clinical trials with Antineoplastons A10 and AS2-1 in different forms of cancer. Five of these trials have reached the final point and proved anticancer activity in various types of malignant brain tumors.

CAN-1: Results in 35 Evaluable Of 43 Total Patients

Complete response (CR) 25.7%
Partial response (PR) 22.9%
Stable disease (SD) 31.4%
CR+PR (objective response) 48.6%
CR+PR+SD 80%
Progressive disease 20%
The largest group of patients was diagnosed with glioblastoma multiforme and the second largest with anaplastic astrocytoma.

BT-9: Phase II Study of Primary Brain Tumors in 13 Evaluable of 20 Patients

Complete response (CR) 23.1%
Partial response (PR) 30.8%
Stable disease (SD) 38.5%
CR+PR (objective response) 53.8%
CR+PR+SD 92.3%
Progressive disease 7.7%
Most of the patients were diagnosed with astrocytoma.

BT-11: Phase II Study of Brain Stem Gliomas in 18 Evaluable of 25 Patients

Complete response (CR) 16.7%
Partial response (PR) 22.2%
Stable disease (SD) 27.8%
CR+PR (objective response) 38.9%
CR+PR+SD 66.7%
Progressive disease 33.3%

BT-13: Phase II Study in Children with Low Grade Astrocytoma in 8 Evaluable of 9 Patients

Complete response (CR) 37.5%
Partial response (PR) 25%
Stable disease (SD) 37.5%
CR+PR (objective response) 62.5%
CR+PR+SD 100%
Progressive disease 0%

BT15: Phase II Study in Adult Patients with Anaplastic Astrocytoma in l6 Evaluable of 23 Patients

Complete response (CR) 12.5%
Partial response (PR) 12.5%
Stable disease (SD) 37.5%
CR+PR (objective response) 25%
CR+PR+SD 62.5%
Progressive disease 37.5%
The patients treated were diagnosed with anaplastic astrocytoma which did not respond to radiation therapy
and/or chemotherapy.

BT-18: Phase II Study of Mixed Gliomas in 11 Evaluable of 14 Patients

Complete response (CR) 27.3%
Partial response (PR) 9.1%
Stable disease (SD) 18.2%
CR+PR (objective response) 36.4%
CR+PR+SD 54.6%
Progressive disease 45.4%
The patients treated were diagnosed with mixed glioma.


Adverse Effects to High-Dose Treatment

Almost all patients experience increased urine output and slight thirst. The treatment usually is free from adverse reactions or is associated with mild side effects.

Moderate side effects (Grade 2 by NCI criteria) include fluid retention, hypernatremia, hypocalcemia, hypokalemia, hypomagnesemia, nausea and vomiting, elevation of SGPT, leukopenia, allergic skin rash, fever, chills headache, tinnitus and decreased hearing and blurred vision.

Severe adverse reactions (Grade 3 and 4 by NCI criteria) were observed in only a small number of cases and included high serum sodium levels (0.9%); low calcium levels (0.6%); low magnesium levels (0.3%); low potassium levels (0.3%); elevations of serum bilirubin (0.3%), SGOT (0.2%), and SGPT (0.3%); and thrombocytopenia (1.1%) It is suspected that in many cases, neurologic toxicity, visual toxicity and ototoxicity resulted from the brain tumors. Serious thrombocytopenia occurred in only one patient who received combination chemotherapy 6 weeks before administrations, which could have contributed to bone marrow suppression. Generally, adverse reactions were fully reversible.

NOTE: Most patients who come to Dr. Burzynski already have failed at least one type of therapy and many have failed more than one type. Many of these patients are considered to be in the final stages of cancer and have no remaining conventional treatment options available to them.


Plaats een reactie ...

Reageer op "Resultaten van Burzynski trials"


Gerelateerde artikelen